174 related articles for article (PubMed ID: 19746526)
1. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
[No Abstract] [Full Text] [Related]
2. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
3. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
[No Abstract] [Full Text] [Related]
4. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab, sunitinib: osteonecrosis of the jaw.
Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
[No Abstract] [Full Text] [Related]
6. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Snider KL; Maitland ML
Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity of new agents.
Maitland ML
Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
[No Abstract] [Full Text] [Related]
8. New study sheds light on angiogenesis inhibitors.
McBride D
ONS Connect; 2009 Jun; 24(6):21. PubMed ID: 19552190
[No Abstract] [Full Text] [Related]
9. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
[TBL] [Abstract][Full Text] [Related]
10. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
14. Bevacizumab in breast cancer: the best is yet to come?
Puhalla S; Brufsky A
Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
[No Abstract] [Full Text] [Related]
15. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
Mansueto G; Longo F
Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
[No Abstract] [Full Text] [Related]
16. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ
Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Girardi F; Franceschi E; Brandes AA
Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
[TBL] [Abstract][Full Text] [Related]
19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
DeMichele A; Fox KR
Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
[No Abstract] [Full Text] [Related]
[Next] [New Search]